In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

GSK licenses US nonprescription rights to Roche's orlistat

Executive Summary

In exchange for SEK120mm ($100mm), GlaxoSmithKline Consumer Healthcare licensed the US rights from Roche to sell the obesity drug orlistat over the counter. Roche, which also stands to get milestones and royalties from the deal, currently sells orlistat as a prescription product under the brandname Xenical.
Deal Industry
  • Pharmaceuticals
    • OTC, Consumer
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register